Notable Raises $40M in Series B Funding

cancerNotable, a Foster City, California-based developer of a clinically validated platform that advances cancer drug development, raised $40M in Series B funding.

The round, which brings total funding to over $55M, was co-led by B Capital Group and LifeForce Capital with participation from Industry Ventures.

The company will use the funds to advance its development efforts.

Led by Matt De Silva, founder, Notable operates a clinically validated platform that advances cancer drug development. Its approach can help predict which types of patients are most likely to respond to a drug in as little as 5 days. This can help patients and their physicians make informed decisions about which clinical trials will be most effective, while also increasing the likelihood of a trial’s success.

The company’s approach has been validated in multiple independent clinical studies conducted by Stanford University, MD Anderson Cancer Center, University of California San Francisco, Rady Children’s Hospital, and Texas Children’s Hospital, among others.



Join the discussion